AnaptysBio, Inc. $ANAB Shares Purchased by Granahan Investment Management LLC

Granahan Investment Management LLC raised its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 12.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 147,773 shares of the biotechnology company’s stock after acquiring an additional 16,118 shares during the period. Granahan Investment Management LLC’s holdings in AnaptysBio were worth $4,525,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Assenagon Asset Management S.A. grew its holdings in shares of AnaptysBio by 4,852.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after acquiring an additional 822,975 shares during the last quarter. 683 Capital Management LLC lifted its holdings in shares of AnaptysBio by 155.6% during the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $11,100,000 after purchasing an additional 304,373 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of AnaptysBio by 145.6% during the third quarter. Arrowstreet Capital Limited Partnership now owns 370,458 shares of the biotechnology company’s stock valued at $11,343,000 after purchasing an additional 219,648 shares during the last quarter. Soleus Capital Management L.P. boosted its position in shares of AnaptysBio by 214.6% in the 2nd quarter. Soleus Capital Management L.P. now owns 321,040 shares of the biotechnology company’s stock valued at $7,127,000 after purchasing an additional 218,988 shares during the period. Finally, Two Sigma Investments LP boosted its position in shares of AnaptysBio by 10.8% in the 3rd quarter. Two Sigma Investments LP now owns 256,420 shares of the biotechnology company’s stock valued at $7,852,000 after purchasing an additional 25,051 shares during the period.

AnaptysBio Trading Down 0.0%

Shares of NASDAQ:ANAB opened at $64.78 on Tuesday. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -124.57 and a beta of 0.32. AnaptysBio, Inc. has a 1 year low of $15.32 and a 1 year high of $66.73. The business has a fifty day simple moving average of $52.18 and a 200 day simple moving average of $41.12.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%.The firm had revenue of $108.25 million for the quarter, compared to the consensus estimate of $87.09 million. On average, sell-side analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its board has authorized a share repurchase plan on Friday, November 21st that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling at AnaptysBio

In related news, Director Magda Marquet sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $48.23, for a total transaction of $530,530.00. Following the transaction, the director owned 9,930 shares of the company’s stock, valued at approximately $478,923.90. This trade represents a 52.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Faga sold 14,281 shares of AnaptysBio stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total transaction of $638,503.51. Following the completion of the sale, the chief executive officer owned 479,344 shares of the company’s stock, valued at $21,431,470.24. This trade represents a 2.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 128,055 shares of company stock worth $5,988,922 over the last quarter. Insiders own 33.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on ANAB shares. Stifel Nicolaus boosted their price objective on AnaptysBio from $56.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Truist Financial raised their target price on shares of AnaptysBio from $36.00 to $50.00 and gave the stock a “hold” rating in a report on Friday, March 6th. Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, January 21st. UBS Group started coverage on shares of AnaptysBio in a research report on Wednesday, January 7th. They issued a “buy” rating and a $70.00 price target for the company. Finally, Wall Street Zen lowered shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $76.22.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.